StockNews.com upgraded shares of Myriad Genetics (NASDAQ:MYGN - Free Report) from a hold rating to a buy rating in a research note released on Tuesday morning.
MYGN has been the topic of several other reports. Bank of America cut their target price on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating on the stock in a research note on Monday, March 3rd. Leerink Partnrs cut shares of Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research report on Monday, December 9th. Raymond James restated an "outperform" rating and issued a $19.00 target price (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. The Goldman Sachs Group dropped their price target on Myriad Genetics from $29.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Finally, Craig Hallum started coverage on Myriad Genetics in a research note on Wednesday, February 12th. They issued a "buy" rating and a $29.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $21.89.
Check Out Our Latest Analysis on Myriad Genetics
Myriad Genetics Trading Down 3.7 %
Shares of MYGN stock traded down $0.34 during mid-day trading on Tuesday, hitting $8.88. The company's stock had a trading volume of 599,366 shares, compared to its average volume of 877,958. The company has a market cap of $810.82 million, a PE ratio of -6.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The company's fifty day simple moving average is $11.76 and its 200-day simple moving average is $16.57. Myriad Genetics has a 52 week low of $8.70 and a 52 week high of $29.30.
Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The business had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. As a group, equities research analysts expect that Myriad Genetics will post -0.3 earnings per share for the current fiscal year.
Institutional Trading of Myriad Genetics
Institutional investors have recently made changes to their positions in the company. Nordea Investment Management AB grew its position in Myriad Genetics by 117.0% in the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company's stock worth $4,548,000 after purchasing an additional 179,527 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Myriad Genetics by 144.2% in the 4th quarter. Jennison Associates LLC now owns 59,015 shares of the company's stock worth $809,000 after buying an additional 34,853 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Myriad Genetics by 6.4% in the fourth quarter. Victory Capital Management Inc. now owns 61,341 shares of the company's stock valued at $841,000 after acquiring an additional 3,711 shares in the last quarter. Barclays PLC increased its position in shares of Myriad Genetics by 136.9% during the third quarter. Barclays PLC now owns 190,243 shares of the company's stock valued at $5,210,000 after acquiring an additional 109,931 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Myriad Genetics by 26.7% during the third quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company's stock valued at $29,135,000 after acquiring an additional 224,255 shares during the last quarter. Institutional investors own 99.02% of the company's stock.
Myriad Genetics Company Profile
(
Get Free Report)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Further Reading
Before you consider Myriad Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.
While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
